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Lysyl oxidase expression is an independent marker of prognosis
and a predictor of lymph node metastasis in oral and
oropharyngeal squamous cell carcinoma (OSCC)
Abstract
Proteins of the lysyl oxidase (LOX) family are important modulators of the extracellular matrix.
However, they have an important role in the tumour development as well as in tumour progression. To
evaluate the diagnostic and prognostic value of the LOX protein in oral and oropharyngeal squamous
cell carcinoma (OSCC) we performed QRT-PCR and immunohistochemical analysis on two tissue
microarrays (622 tissue samples in total). Significantly higher LOX expression was detected in high
grade dysplastic oral mucosa as well as in OSCC when compared to normal oral mucosa (P < 0.001).
High LOX expression was correlated with clinical TNM stage (P = 0.020), lymph node metastases for
the entire cohort (P < 0.001), as well as in the subgroup of small primary tumours (T1/T2, P < 0.001).
Moreover, high LOX expression was correlated with poor overall survival (P = 0.004) and disease
specific survival (P = 0.037). In a multivariate analysis, high LOX expression was an independent
prognostic factor, predicting unfavourable overall survival.In summary, LOX expression is an
independent prognostic biomarker and a predictor of lymph node metastasis in OSCC. Moreover, LOX
overexpression may be an early phenomenon in the pathogenesis of OSCC and thus an attractive novel
target for chemopreventive and therapeutic strategies. (c) 2009 UICC.
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Our data emphasize LOX as an attractive novel target for oral cancer therapeutic and 
chemopreventive strategies. Our results may facilitate identification of high-risk patients with 
increased metastatic potential at the time point of clinical tumour diagnosis who may benefit 
from more aggressive local treatments. Finally, it may help in the development of new, more 
effective strategies for targeted chemoprevention and treatment of oral cancer.  
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Abstract 
Proteins of the lysyl oxidase (LOX) family are important modulators of the extracellular 
matrix. However, they have an important role in the tumour development as well as in tumour 
progression. To evaluate the diagnostic and prognostic value of the LOX protein in oral and 
oropharyngeal squamous cell carcinoma (OSCC) we performed QRT-PCR and 
immunohistochemical analysis on two tissue microarrays (622 tissue samples in total). 
Significantly higher LOX expression was detected in high grade dysplastic oral mucosa as 
well as in OSCC when compared to normal oral mucosa (P < 0.001). High LOX expression 
was correlated with clinical TNM stage (P = 0.020), lymph node metastases for the entire 
cohort (P < 0.001), as well as in the subgroup of small primary tumours (T1/T2, P < 0.001). 
Moreover, high LOX expression was correlated with poor overall survival (P = 0.004) and 
disease specific survival (P = 0.037). In a multivariate analysis, high LOX expression was an 
independent prognostic factor, predicting unfavourable overall survival.  
In summary, LOX expression is an independent prognostic biomarker and a predictor of 
lymph node metastasis in OSCC. Moreover, LOX overexpression may be an early 
phenomenon in the pathogenesis of OSCC and thus an attractive novel target for 
chemopreventive and therapeutic strategies. 
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 Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common human 
cancer in the western world and is associated with high morbidity and low survival1,2. 
HNSCC comprises a heterogeneous group of tumours located at different anatomic sites, 
including the oral cavity, nasopharynx, oropharynx, hypopharynx and larynx, each of which is 
characterized by different clinical behaviour. Local or regional disease recurrence occur in 
one third of patients with advanced tumour stages (stage III and IV) and distant metastases 
appear in 25% of patients despite bi- or trimodality standard treatments3. Novel molecular 
predictive biomarkers of regional and distant metastatic potential at the time of diagnosis are 
urgently needed to guide clinical therapy decisions.  
Identification and evaluation of new molecular parameters are of outmost importance in 
OSCC. Using tissue microarrays, it is now possible to perform large-scale expression analysis 
to identify candidate biomarkers. Previously, we have demonstrated that the combination of 
tumour tissue microarrays and cDNA arrays is a powerful approach to rapidly identify and 
further evaluate genes that play a role in tumour biology4. Here, we used the tissue microarray 
approach to identify candidates in OSCC. Since we focus our research on hypoxia-related 
proteins5, we have selected for this thorough analysis lysyl oxidase (LOX), an extracellular 
matrix protein, which was identified to be overexpressed in human hypoxic cells6.  
Lysyl oxidase, a copper-dependent metalloenzyme that belongs to the lysyl oxidase gene 
family, acts as an extracellular modulating enzyme and initiates the covalent cross-linking of 
collagens and elastin in extracellular matrice (ECM)7-9 and is essential for normal connective 
tissue function, embryonic development, and wound healing10, 11. However, LOX can function 
also intracellularly, regulating cell signalling and gene expression12. Interestingly, LOX was 
originally identified as a tumour suppressor in non-tumorigenic revertants of ras-transformed 
fibroblasts13, 14. Concerning human cancer there are several reports describing reduced LOX 
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expression in cancer patients, supporting the idea that LOX acts as a tumour suppressor7, 15-17. 
In contrast, recent publications have demonstrated  up-regulation of the LOX mRNA as well 
as of the LOX protein in various cell lines and tumour tissues (including head and neck 
cancer, breast cancer and lung cancer etc)18,19. Several studies evaluated the relationship 
between tumour behaviour and LOX protein expression in vitro and in vivo with inconsistent 
and inconclusive results18, 19.  
So far, the significance of LOX proteins in head and neck squamous cell carcinoma is 
controversial. While in some studies LOX was shown to be upregulated in oral squamous cell 
carcinoma20 and to be essential for hypoxia-induced metastasis in HNSCC19, reports on LOX 
and LOXL2 down-regulation in head and neck cancer patients also exist15.  
In order to investigate the predictive and prognostic significance of the lysyl oxidase in 
malignant tumour tissue samples derived from OSCC patients we have implemented a 
comprehensive analysis of the LOX protein on tissue microarrays.  
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Material and Methods 
Patients 
 Consecutive patients who presented at the Ear Nose and Throat Department of the 
University Hospital Zurich between 1993 and 2000 with histologically proven previously 
untreated oral or oropharyngeal squamous cell carcinoma were included.  
A review of the records identified 267 patients fulfilling the entry criteria. Fifteen of these 
were subsequently excluded because of the small size of the biopsy (n=8), previous or 
synchronous malignancies (n=4), intercurrent death (n=1), lack of follow-up (n=2). Finally, 
primary tumour tissues of 252 patients were enrolled into this study. Furthermore, 93 biopsies 
of oral mucosa with different degrees of dysplasia (14 samples of low grade and 79 samples 
of high grade dysplasia), as well as 20 samples from hyperplastic mucosa, 20 samples from 
non-neoplastic ulceration derived from oral cavity and oropharynx were assessed for LOX 
expression. For the evaluation of dysplastic changes a simplified WHO classification was 
used. Mild dysplasia (SIN 1) was considered low grade dysplasia, whereas moderate 
dysplasia (SIN 2) and severe dysplasia/carcinoma in situ (SIN 3) were considered high grade 
dysplasia. 
In addition, normal mucosa samples of 60 patients not suffering from tumour disease 
derived from palate, tongue and buccal mucosa were collected to serve as controls. With the 
approval of the regional board of the Medical Ethics Commission, paraffin-embedded tissue 
samples were obtained from the archives of the Institute of Surgical Pathology. The 
histopathological diagnosis and grading of biopsies were reviewed by an experienced 
pathologist (I.H.). Clinicopathological co-variables were derived from patient charts. The 
principal clinical characteristics of the patient cohort are summarized in Table 1. 
Patients in this study were treated according to recommendation of the Swiss Head and 
Neck Cancer Society. Basically, the treatment decisions were made based on the clinical and 
pathological TNM diagnosis. The treatment decision did not account for the oxygenation 
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status. 115 (45,6%) out of 252 patients were treated with surgery alone, 22 (8,7%) with 
radiation only, 86 (34,1%) with surgery and radiation, 16 (6,4%) with surgery, radiation and 
chemotherapy, as well as 13 (5,2%) with radiation and chemotherapy. In the surgery group 
(surgery without or with radiotherapy and/or chemotherapy) in 178 (70,6%) patients 
additional neck dissection was performed. No neck dissection was performed in 39 (15,5%) 
patients of the surgery group and in 35 (13,9%) patients treated with radiotherapy alone or 
with chemotherapy. 
 
RNA extraction and Quantitative Reverse Transcription-Polymerase Chain Reaction 
In addition to paraffin-embedded tissue samples in 7 patients with OSCC also fresh frozen 
tissue samples with corresponding normal tissue from distant region were available. The 
localization of normal mucosa samples was adjacent, but not in close vicinity to the patient 
primary tumor. The samples were used as normal controls only in cases where 
macroscopically and histological examination revealed  normal epithelial tissue without any 
signs of abnormal tissue architecture or tumor disease. These samples were also obtained at 
time of surgery for OSCC at the Ear Nose and Throat Department of the University Hospital 
Zurich, after approval of the regional board of the Medical Ethics Commission. The 
histopathological diagnosis and grading of biopsies were reviewed by an experienced 
pathologist (I.H.). Clinicopathological co-variables were derived from patient charts. Tissue 
samples were fresh frozen in liquid nitrogen and stored at –80°C before RNA extraction.  
For RNA extraction 15-20 of 30µm thick frozen sections were prepared with a 
cryomicrotome and transferred to a chilled 1.5 ml eppendorf tube. RNA isolation was 
performed using the RNeasy RNA mini kit (Qiagen, Valencia, CA) employing the tissue 
homogenizer Ultra-Turrax T8 (IKA-Werke) according to supplier’s instructions. Following 
isolation procedure, RNA concentration and RNA degradation were checked using the 
Agilent 2100 Bioanalyzer (Agilent Technologies). Tissue quality of the isolated RNA was 
Page 7 of 28
John Wiley & Sons, Inc.
International Journal of Cancer
determined with a NanoDrop ND 1000 (NanoDrop Technologies, Delaware, USA) and a 
Bioanalyzer 2100 (Agilent, Waldbronn, Germany). Only those samples with a 260 nm/280 
nm ratio between 1.8-2.1 and a 28S/18S ratio within 1.5-2 were further processed.  
The LOX forward and reverse primer were “CAGAGGAGAGTGGCTGAAGG”, and 
“CCAGGTAGCTGGGGTTTACA” respectively, synthesized by Microsynth Company 
(Balgach, Switzerland). The RT-PCR reaction was performed using LightCycler®FastStart 
DNA Master SYBR Green I (Roche). PCR conditions were as follows: 42 cycles, 95°C for10 
min, 95°C for 10 sec, 57°C for 6 sec, 72°C for 3 sec, 72°C for 1 min. 
 
Tissue microarray preparation 
Two tissue microarrays were constructed as described previously4. Briefly, suitable areas 
for tissue retrieval were marked on routine haematoxylin and eosin (H&E) sections, punched 
out of the paraffin block and inserted into recipient block. The tissue arrayer was purchased 
from Beecher Instruments (Woodland, USA). The punch diameter was 0,6 mm. The OSCC-
TMA was constructed to represent 429 samples (252 primary tumour samples, 128 samples of 
lymph node metastasis, 29 samples of recurrent tumours and 20 normal mucosa samples). The 
whole OSCC-TMA was accomplished on six paraffin blocks using cores from different areas 
of each tumour in order to account for tumour heterogeneity. A second premalignant tissue 
PMT-TMA with 193 samples was constructed using 93 tissue samples from dysplastic 
mucosa (14 samples of low grade and 79 samples of high grade dysplasia), 20 samples from 
hyperplastic mucosa, 20 samples from non-neoplastic ulceration and 60 samples from normal 
oral mucosa. Also this TMA was accomplished on six paraffin blocks. After the block 
construction was completed, 4.0µm sections of the resulting tissue microarray block were cut 
for further analysis. 
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Immunohistochemistry 
LOX immunohistochemistry was performed on paraffin sections of formalin-fixed tissue 
on TMA, using a Ventana Benchmark automated staining system (Ventana Medical Systems, 
Tucson, Arizona) as described elsewhere21. The samples were deparaffinised and blocked by 
incubation for 10 min with a 3% goat serum in TBS for 20 min. Antigen retrieval was 
achieved by cooking in 0,01 M citrate buffer for 5 min. Primary polyclonal rabbit anti-LOX 
antibody (a gift from Dr. D. Kirschmann, University of Iowa) was added to the slides for 60 
min at room temperature and revealed with the iVIEW DAB detection kit, yielding a brown 
reaction product. The signal was enhanced with the Ventana amplification kit. Slides were 
counterstained with haematoxylin prior to glass coverslipping. As a negative control we 
included sections where primary antibody was replaced by nonhuman reactive rabbit IgG 
(DAKO).   
 
Evaluation of LOX Immunostaining   
All immunohistochemical specimens were analyzed independently by 2 investigators 
(A.A., I.H.), who were blinded to the clinical information pertaining to the subject. Only 
cytoplasmic immunoreactivity of epithelial cells was regarded as LOX expression. Staining 
localized in the stromal component was not considered. An immunoreactivity score (IRS), 
modified from the German IRS 22 was calculated multiplicating percentage of positive cells 
(PP) with staining intensity (SI). To calculate the IRS, we assigned the following points for 
PP: 0 = 0%; 1 = 1% to 20%; 2 = 21% to 40%; 3 = 41% to 60%; 4 = 61% to 80%; 5 = 81% to 
100%. The staining intensity was rated on a scale 0 to 3, with 0 = negative; 1 = weak; 2 = 
moderate; 3 = strong staining intensity. On the basis of PP and SI the IRS could range from 0 
to 15. The median IRS of all samples, which was 8, was used to categorize the cases as high 
LOX expression (IRS≥ 8) and low LOX expression (IRS< 8). The consensus opinions were 
used to assign final IRS scores to the disputed cases before data analysis. To evaluate 
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intratumoural heterogeneity of LOX expression we additionally stained 10 conventional tissue 
slides with OSCC. 
 
Statistical analyses 
 The statistical analyses were carried out using the SPSS for Windows 15.0.1 for windows 
(SPSS Inc, Chicago, IL). Overall survival (OS) was defined as the time between diagnosis 
and time of death of the patient or until the last follow-up visit and disease specific survival 
(DSS), was defined as time between diagnosis and death of cancer or until the last follow-up 
visit. Survival curves were calculated using the Kaplan-Meier method, with significance 
evaluated using 2-sided log-rank statistics. The chi-square test was used to evaluate the 
relationship between LOX expression and clinical and pathological features. Continuous 
baseline variables were dichotomized as follows; T-category (T1/2/ Vs T3/4), N-category 
(N0/ Vs N1/2/3). Wilcoxon tests were used to examine the relationships of LOX expression 
between primary tumours and lymph node metastases. Cox regression analysis was performed 
to determine if LOX status is an independent risk factor for overall survival (OS) in both the 
univariable and multivariable level. Inclusion criteria for covariates and confounders for entry 
into the multivariate analysis was a p-value < 0.1 in the univariable analysis. A backward 
elimination procedure was then performed to eliminate nonsignificant variables (P > 0.1). 
Probability values less than 0.05 were regarded as significant. 
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 Results  
Analysis of the LOX expression by Quantitative Reverse Transcription-Polymerase Chain 
Reaction (QRT-PCR) 
To demonstrate that LOX is up-regulated in squamous cell carcinoma in comparison 
with normal oral mucosa we applied QRT-PCR analysis on paired tumour samples with 
corresponding normal oral mucosa. Seven human OSCC tumour and normal mucosa samples 
from patients included in the tissue microarray analysis were used for QRT-PCR. Expression 
of LOX in each sample was normalized by the expression of 18s rRNA. The ratio of LOX 
expression in tumour tissue to normal tissue was regarded as the relative quantitative mRNA 
expression of LOX. As shown in Fig. 1, levels of LOX mRNA were increased in 5 out of 7 
patients when compared with corresponding normal tissue samples.  .  
 
Expression pattern of the LOX protein in normal oral mucosa, premalignant lesions and in 
squamous cell carcinoma of the oral cavity and oropharynx 
 Immunohistochemistry of LOX was performed to evaluate the expression of this marker 
in 429 tissue samples derived from 252 patients with histologically confirmed OSCC. 
Moreover, LOX expression in premalignant lesions and control samples was evaluated on 
additional 193 samples on TMA (Fig. 2). LOX immunoreactivity in normal oral mucosa 
(NOM) and hyperplastic oral mucosa (HYP) was mainly weak and localized suprabasal in the 
lower half of the oral mucosa (Fig 2A; NOM, HYP). The median of the immunoreactivity 
score (IRS) was 3 and 3.5 for NOM and HYP respectively (Fig 2B; NOM, HYP). 
Heterogeneous LOX immunoreactivity was detected in low grade dysplastic epithelia with a 
median IRS of 3 (Fig 2A; LGD). Interestingly a strong and diffusely distributed LOX 
immunoreactivity was detected in high grade dysplastic epithelia (Fig 2A; HGD) and a 
mainly strong but heterogeneously distributed LOX positivity was observed in OSCC tissue 
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(Fig 2A; OSCC), with median value of IRS of 10 and 8 respectively (Fig 2B, HGD and 
OSCC). The distribution of LOX is depicted with boxplot, where each plot represents the 
median, upper and lower quartiles as well as minimum and maximum data values and outliers 
(Fig 2B). The differences of LOX immunoreactivity between each tissue samples were 
significant as showed by Kruskal and Wallis H-test (P < 0.001). The median value of 
immunoreactivity score for LOX in all OSCC samples (median = 8) was used as a cutoff to 
differentiate tumour positivity. Low LOX expression was defined as negative or weak 
cytoplasmic staining (IRS <8), whereas high LOX expression was defined as moderate or 
high cytoplasmic staining with IRS ≥8. Table 2 summarizes the immunohistochemical results 
for non-, pre- und malignant oral mucosa on the TMA. The cytoplasmic LOX expression was 
increased in high grade dysplastic mucosa and OSCC with positive lymph node status 
 
LOX expression and clinical and pathological characteristics  
Using Person’s chi-square test the LOX expression in OSCC samples was analysed for 
relationship with clinical and pathological parameters. No relation was identified between 
age, histological grade, T-stage and expression of LOX (Table 3). There was also no 
difference in LOX protein expression between different anatomic localisations (tongue, base 
of the tongue, floor of the mouth; data not shown). However, significant relation was 
observed between the lymph node status and the LOX expression (P < 0.001) when 
evaluating the entire patient population. High LOX expression was seen in regionally lymph 
node metastasized tumours (N1 to N3, UICC) compared with regionally non-metastatic 
tumours (N0) (Table 3). Moreover, significant relation was observed between clinical stage 
and the LOX expression (P = 0.020). High LOX expression was detected in advanced-stage 
tumours (Table 3). 
In our group of patients, 178 (70,6%) had small tumours (T1 and T2; < 4cm). In this 
group of small primary OSCC high LOX expression was significantly associated with lymph 
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node status (P < 0.001). Furthermore, for patients with T1 or T2 tumours, only 33 out of 81 
(40,7%) patients with low LOX expression had evidence of regional lymph node metastases, 
whereas 70 out of 97 (72%) patients with high LOX expression developed lymph node 
metastases. For all OSCC tumours, when using high LOX level as a predictor of 
pathologically proven lymph node metastases, the sensitivity was 75% and the specificity was 
58%. For the small primary OSCC tumours (T1 and T2) the sensitivity was 72% and the 
specificity was 59%.   
 
LOX expression and patient survival  
To determine whether the level of LOX protein expression is associated with overall 
survival (OS) and disease specific survival (DSS) of OSCC patients, we performed univariate 
survival analysis. This analysis was performed for the entire patient cohort (Fig 3C, D) as 
well as for patient suffering from oropharyngeal (Fig 3B) and oral cavity carcinoma (Fig 3A), 
separately. As shown in Figure 3 high LOX expression correlated with poor overall survival 
independently whether the primary tumour localisation was oral cavity (P = 0.023, log rank), 
oropharynx (P = 0.050, log rank), or the whole patient cohort was analysed (P = 0.004 for OS 
and 0.037 for DSS, log rank).   
In univariate analysis, several factors were statistically significantly associated with 
overall survival, including sex, T stage, N stage, clinical stage and LOX expression (Table 4). 
We then performed a Cox proportional hazards regression analysis to determine whether the 
effect of LOX expression on overall survival is dependent on other known risk factors. In the 
subsequent multivariate analysis both T stage and LOX expression was associated with worse 
overall survival (P < 0.001 and P = 0.042, respectively; Table 4).  
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Discussion 
In the present study we performed analysis of the LOX protein on a large cohort of 
patients suffering from oral and oropharyngeal squamous cell carcinoma. This is the first 
report of LOX protein expression analysis including samples from normal mucosa, 
precancerous lesions and OSCC tumour samples. 
In previous reports, differences in chromosomal pattern, carcinogenic progression and disease 
course in patients with squamous cell carcinoma of the head and neck were observed, but 
there was a relationship to the primary tumour localisation23. In order to analyze a 
homogeneous patient cohort, only OSCC patients with primary manifestation in the oral 
cavity and oropharynx were included in this study and analysed together as well as separately. 
Moreover, only patients who underwent standard therapy protocols and who were accessible 
for follow up for a minimum of 5 years were included.  
In this project we have focused on the role of the lysyl oxidase protein in OSCC. With the 
implementation of the TMA technology we analysed the association between 
clinicopathological data and expression levels of the LOX protein. Different LOX expression 
levels were observed in non-, pre- and malignant oral mucosa. Concerning LOX protein our 
data demonstrate that increasing levels of LOX expression are associated with high grade 
dysplasia and with advanced-stage tumours. 
High LOX expression in the primary tumour was highly indicative for the simultaneous 
presence of lymph node disease (P < 0.001), independently of the primary tumour stadium. 
Furthermore, the LOX protein expression correlated not only with advanced tumour stage, 
and lymph node metastasis, but also a clear correlation with overall survival and disease 
specific survival was observed (P < 0.004 and P < 0.037).  
Heavy smoking, alone and in combination with high level of alcohol consumption are 
well established risk factor for HNSCC24. Regardless of tobacco and alcohol use, also 
exposure to HPV shows increased association especially with oropharyngeal carcinoma25-27. 
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Therefore two distinct pathways were proposed for the oropharyngeal cancer development: 
one driven mostly by the carcinogenic effects of alcohol and tobacco use (or combination of 
these) and the other one by HPV induced genomic instability25. In our patient cohort high 
LOX expression was associated with impaired overall survival independently whether the 
primary tumour was localised in the oral cavity or oropharynx.  This could implicate that the 
LOX expression is not essential for the HPV associated cancer development. In order to 
clarify the role of the LOX protein in HPV related cancerogenesis, we have initiated an 
independent risk analysis of the HPV infection in regard to disease outcome as well as in 
regard to LOX expression in oropharyngeal squamous cell carcinoma. 
Outcome indicators in cancer patients are in general derived from clinical and 
pathological features28. However, currently it is impossible to reliably predict treatment 
outcomes, even in patients within the same TNM category29. Other clinical and pathological 
variables, not included in the TNM system, have been identified as prognostic predictor 
variables30-33.  
Surprisingly, the nodal status was in our cohort significant negative prognostic factor only 
in the univariate analysis. Similar results were observed by Pedruzzi et al.34. This could be 
partially explained by the analysis of a cohort of consecutive patient at our institute regardless 
of the applied therapy modality. This very interesting observation requires further 
examination. 
In head and neck carcinoma LOX down as well up regulation was described: Initially, 
LOX was shown to be up regulated in oral squamous cell carcinoma  as well as in oral 
submucous fibrosis20. Rost et al. 15 have observed the reduction of LOX as well as of LOXL-2 
mRNA expression in cell lines as well as tissue samples originating from HNSCC. Erler et 
al.19 observed association between LOX overexpression and decreased overall survival in head 
and neck cancer patients. LOX was also included among the endogenous molecular markers 
indicative of hypoxia in HNSCC and indicative for shorter overall survival35.  
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Recently, Shieh et al.36 have demonstrated up regulation of LOX mRNA as well as 
increased LOX protein expression in OSCC associated with areca nut. Interestingly, in their 
experimental setting precancerous lesions displayed the highest LOX mRNA expression. 
These recent report support our observations of dynamic LOX protein up regulation in oral 
squamous carcinoma, with low LOX protein expression in normal oral mucosa, hyperplastic 
oral mucosa and in low grade dysplastic tissue. In our experimental setting tumour tissue 
samples of OSCC displayed up regulation of the LOX protein expression when compared 
with normal mucosa and low grade dysplasia, however in agreement with results observed on 
RNA level by Shieh et al. we have observed highest LOX protein expression levels in high 
grade dysplastic tissue. At this point it is tempting to speculate about the role of the LOX 
protein in cancer progression in OSCC. The here observed up regulation of the LOX protein 
in precancerous lesions may represent a crucial step allowing for modification and modulation 
of the ECM environment and allow the further progression and metastatic spread of the 
neoplastic process. However, for clearer understanding of the metastatic progression in 
OSCC, further functional studies are needed. 
Interestingly, in a recent study a similar pattern of expression of the LOX4 protein in 
premalignant  lesions and HNSCC was observed37. 
There is some controversy concerning the biologic relevance of LOX protein in molecular 
pathogenesis of invasive carcinomas. Interestingly, initially LOX was first identified as a “ras 
recision gene” in normal cells transformed by LTR-c-H-ras. A putative ras-related tumour 
suppressor function had been attributed to LOX in transformed fibroblasts38-40 41-44. A 
decrease in LOX activity was noted in different malignant cell lines including fibrosarcoma, 
rhabdomyosarcoma, and choriocarcinoma45. Consistent with these reports, poorly invasive/ 
non-metastatic breast cancer, uveal and cutaneous melanoma, and rat prostate cancer cell lines 
were shown to express little to no LOX 18. Csiszar et al.46 demonstrated a decrease in LOX 
expression in colon tumours and Ren et al.47 described a progressive reduction of LOX 
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expression with the transition from normal prostate epithelium to malignant prostate 
epithelium. 
Subsequently however, both up- and down-regulation of LOX was noted not only in cell 
lines but also in tumour tissue, e.g. in squamous oral, head and neck, gastric, prostate, colon, 
invasive breast, lung and renal carcinoma. Up-regulation in LOX expression was observed in 
some osteosarcoma cell lines48 and certain malignant tumours49,50. In addition, Stassar et al. 
demonstrate that LOX expression is significantly associated with a higher staging in clear cell 
renal carcinoma tissues51. 
Systematic studies have been directed mostly at the role of LOX in invasive breast 
carcinoma cells. These studies revealed, that LOX activity was essential for promotion of the 
invasive phenotype of breast carcinoma cells18, 52 and for metastatic behaviour in mice19. 
The reasons for contradictory results of LOX expression in various cancers may be 
multifactorial. Concerning the in vitro experimentally transformed fibroblasts it was 
repeatedly shown that ras oncogene expression results in the establishment of a new 
equilibrium of gene expression patterns which includes gene activation as well as gene 
repression. When using this experimental system one has to keep in mind that the molecular 
effects that result from transient and sustained oncogene expression might be of quite 
different nature. Our own investigations showed that transient ras oncogene expression results 
in activation of different set of genes when compared with sustained ras oncogene 
expression53. Therefore, changes in gene expression patterns observed in vitro must be 
interpreted with caution when applied in vivo. 
Another possible explanation may lie in differences in fluctuations in LOX expression at 
different stages of transformation, in differences in sample size and also in variation in the 
molecular environment in different tissue types. The different modulation of LOX activity in 
different tumours can partially be explained by global genetic differences in particular 
tumours, by different availability of LOX downstream targets or substrates in different cell 
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types54. It is possible that tumorigenic and/or invasive properties can be gained either by LOX 
up or down regulation, in reliance of the intrinsic cellular environment, as well as in 
dependence of natural presence or absence of the LOX protein under normal conditions in a 
particular cell or tissue type. 
In conclusion, our study is the first in examining the expression of the LOX protein in a 
panel of tissue samples representing the particular steps of the carcinogenesis including 
normal mucosa samples, precancerous tissue, as well as tumour tissue samples of OSCC. Our 
results demonstrate that LOX is a specific marker of lymph node metastases in patients with 
this challenging form of carcinoma. Importantly, LOX levels seem to identify a subset of 
patients with early tumour stage primary tumour and high metastatic potential that might 
benefit from more aggressive therapy. However, the appropriate treatment still has to be 
determined for this group of high risk patients. The emerging role of LOX in the metastatic 
process strongly suggests that attenuation of LOX activity may be a potential target for novel 
strategies in the treatment of head and neck as well as other solid carcinomas. As LOX 
inhibition had minimal effects on the growth of the primary tumour36, it is conceivable, that 
combination of anti-LOX therapy with other agents, such as radio-chemotherapy, would act 
supportive to target both primary and metastatic growth. 
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Legends 
Fig. 1., LOX mRNA expression in OSCC tumour tissue samples (T, grey bars) and normal 
tissues samples (N, black bars) examined by quantitative reverse transcription-polymerase 
chain reaction (QRT-PCR). The ratio of LOX expression in tumour tissue to normal tissue 
was regarded as the relative quantitative mRNA expression of LOX. Levels of LOX mRNA 
were increased in 5 out of 7 patients tested when compared with normal tissue samples.  
 
Fig. 2. A, typical staining patterns observed with LOX immunohistochemistry in normal 
mucosa (NOM), low grade (LGD) and high grade dysplastic mucosa (HGD) as well as in the 
squamous cell carcinoma of the oral cavity and oropharynx (OSCC) on high-density tissue 
microarray. Weak LOX immunoreactivity in NOM, HYP and heterogeneous reactivity in 
LGD. Strong homogeneous LOX immunoreactivity in HGD and weak to strong 
heterogeneous immunoreactivity in OSCC (x80). 
B, box plot analysis of immunoreactivity scores of LOX showing a significant increase of IRS 
in high grade dysplasia (HGD) and OSCC compared to normal (NOM), hyperplastic oral 
mucosa (HYP) and low grade dysplastic epithelia (LGD) (P < 0.001, Kruskal and Wallis H-
test). 
 
Fig. 3. Kaplan-Meier survival analysis of oral cavity OSCC (A), oropharynx OSCC (B) as 
well as oral cavity and oropharynx OSCC together (C, D) according to LOX expression.  
Patients with high LOX expression had a significantly inferior overall survival time (A, B, C) 
and disease specific survival (D) than those with low LOX expression in all investigated 
anatomical localisation (P= 0.023 for oral cavity OSCC,  P= 0.050 for oropharyngeal OSCC 
and P= 0.004 for both group together, log rank test).  
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Tables 
 
 
Table 1. Clinicopathological characteristics of the  
               patients in the OSCC tissue microarray 
 
 
Variable N %  
 Eligible patients 252    
 Age (years)     
    Median 55   
    Range 36-81   
 Sex    
    Female 83 33  
    Male 169  67  
 Localisation    
     Oral Cavity 98 38,9  
     Oropharynx 154 61,1  
 Histological grade     
    G1 18 7   
    G2 159 63   
    G3 75  30  
 Tumour stage     
    T1 66 26  
    T2 112 45  
    T3 46 18  
    T4 28  11  
 Nodal stage    
    N0 92 36  
    N1 45 18  
    N2 111 44  
    N3 4 2  
 Follow-up    
    Median length of follow-up (mo) 81   
    Median follow-up 95% CI 71,2-82,8   
 End state    
    Dead 127 50,4  
    Alive 125 49,6  
    
 
 
 
Table 2. Analysis of LOX expression in non-, premalignant and  
               malignant oral mucosa on TMA 
 
   
 
Samples Total LOX low 
No (%) 
Lox high 
No (%) 
 
 
 Normal oral mucosa 80 73 (91) 7 (9)   
 Oral Ulcus 20 16 (80) 4 (20)   
 Hyperplastic oral mucosa 20 17 (85) 3 (15)   
 Low grade dysplastic 
mucosa 
14 13 (93) 1 (7)   
 High grade dysplastic 
mucosa 
79 9 (11) 70 (89)   
 Non-metastasized OSCC 92 51 (55) 41 (45)   
 Metastasized OSCC 160 36 (23) 124 (78)   
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Table 3. LOX and its clinical and pathological correlations 
 
 
  LOX low LOX high P-value  
 Parameters No (%) No (%)   
 Age at diagnosis (≤55/>55)     
      ≤55 43 (17.1) 87 (34.5) 0.691  
      >55 44 (17.5) 78 (31.0)   
 
 Histological grade     
     Well 10  (4.0)    8   (3.2) 0.149  
     Moderate 52 (20.6) 107 (42.5)   
     Poor 25  (9.9)  50  (19.8)   
  T-stage     
     T1 22  (8.7) 43 (17.1) 0.456  
     T2 42 (16.7) 71 (28.2)   
     T3  17  (6.7) 29 (11.5)   
     T4   6   (2.4) 22  (8.7)   
 
  N-stage for all tumours (n=252)     
     N0 51 (20.2) 41 (16.3) < 0.001  
     N1   4   (1.6) 36 (14.3)   
     N2 30 (11.9) 86 (34.1)   
     N3   2   (0.8)   2   (0.8)   
 
  N-stage for T1/T2 tumours (n=178)     
     N0 48 (27.0) 27 (15.2) < 0.001  
     N1   5   (2.8) 23 (12.9)   
     N2 27 (15.2) 47 (26.4)   
     N3   1   (0.6)   0   (0.0)   
 
 M-stage       
    M0 95 (37.7) 156 (61.9)   
    M1  0   (0.0)    1   (0.4)   
 Clinical TNM stage     
    I  19   (7.5)   17   (6.7) 0.020  
    II  20   (7.9)   19   (7.5)   
    III  12   (4.8)   39 (15.5)   
    IVA   42 (16.7)    80 (31.7)   
    IVB      2   (0.8)       2   (0.8)    
      
 
Table 4. Univariate and multivariate survival analysis 
Overall survival All patients (n=252) death events (n=127, 50,4 %)  
 Univariate Analysis Multivariate Analysis 
 RR CI (95%) P RR CI (95%) P 
Age at diagnosis (≤55/>55) 1.01 0.71-1.42 0.972    
Sex (male/female) 1.46 0.99-2.15 0.052 1.32 0.89-1.95 0.169 
Tumour grade (G1-2/G3-4) 0.73 0.48-1.08 0.114    
Tumour stage (T1-2/T3-4) 2.66 1.88-3.77 < 0.001 2.27 1.51-3.42 < 0.001 
Lympn node metastasis (N0/ pN1-3) 
 
1.615 1.11-2.35 0.012 1.01 0.53-1.93 0.981 
Clinical TNM stage (I-II/III-IV) 2.13 1.38-3.27 0.001 1.28 0.58-2.85 0.538 
LOX (low/high) 1.77 1.19-2.63 0.004 1.53 1.01-2.32 0.042 
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